ojrdrtОнкологический журнал: лучевая диагностика, лучевая терапияJournal of oncology: diagnostic radiology and radiotherapy2587-75932713-167XНЕКОММЕРЧЕСКОЕ ПАРТНЕРСТВО «ОБЩЕСТВО ИНТЕРВЕНЦИОННЫХ ОНКОРАДИОЛОГОВ»10.37174/2587-7593-2018-1-1-69-74ojrdrt-64Research ArticleКОМБИНИРОВАННЫЕ МЕТОДЫ ДИАГНОСТИКИ И ЛЕЧЕНИЯCOMBINED METHODS OF DIAGNOSTICS AND TREATMENTПервый опыт применения МРТ/УЗИ fusion-биопсии в диагностике рака предстательной железыThe first Experience of Applying MR/us fusion Biopsy in Prostate Cancer DiagnosisКоссовФ. А.KossovF. A.

Москва

Moscow

fil-doc@yandex.ruКамоловБ. Ш.KamolovB. Sh.

Москва

Moscow

АбдуллинИ. И.AbdullinI. I.

Москва

Moscow

ОлимовБ. П.OlimovB. P.

Москва

Moscow

ОрловО. С.OrlovO. S.

Москва

Moscow

ПановВ. О.PanovV. O.

Москва

Moscow

БуйденокЮ. В.BujdenokYu. V.

Москва

Moscow

ДолгушинБ. И.DolgushinB. I.

Москва

Moscow

ТюринИ. Е.TyurinI. E.

Москва

Moscow

Российская медицинская академия непрерывного профессионального образования Минздрава РоссииРоссияRussian Medical Academy of Continuous Professional EducationRussian FederationЕвропейский медицинский центрРоссияEuropean Medical CenterRussian FederationМосковский государственный медико-стоматологический университет им А.И. ЕвдокимоваРоссияA.E. Evdokimov Moscow State Medical-Stomatological UniversityRussian FederationРоссийская медицинская академия непрерывного профессионального образования Минздрава России; Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина Минздрава РФРоссияRussian Medical Academy of Continuous Professional Education; N.N. Blokhin National Medical Research Center of OncologyRussian FederationНациональный медицинский исследовательский центр онкологии им. Н.Н. Блохина Минздрава РФРоссияN.N. Blokhin National Medical Research Center of OncologyRussian Federation201830032018116974Copyright © Коссов Ф.А., Камолов Б.Ш., Абдуллин И.И., Олимов Б.П., Орлов О.С., Панов В.О., Буйденок Ю.В., Долгушин Б.И., Тюрин И.Е., 20182018Коссов Ф.А., Камолов Б.Ш., Абдуллин И.И., Олимов Б.П., Орлов О.С., Панов В.О., Буйденок Ю.В., Долгушин Б.И., Тюрин И.Е.Kossov F.A., Kamolov B.S., Abdullin I.I., Olimov B.P., Orlov O.S., Panov V.O., Bujdenok Y.V., Dolgushin B.I., Tyurin I.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.oncoradjournal.ru/jour/article/view/64

Частота выявления рака предстательной железы при применении стандартной биопсии колеблется от 31 до 42 %, однако число ложноотрицательных результатов остается чрезмерно высоким. Современные урологические тренды в диагностике рака предстательной железы сводятся к выявлению наиболее злокачественного опухолевого узла (index lesion), который, по сути, и будет определять прогноз заболевания и тактику лечения конкретного больного. В данной работе описана методика проведения и продемонстрированы первые результаты применения МРТ/УЗИ fusion биопсии – технологии, позволяющей выполнять прицельную биопсию предстательной железы из узловых образований, выявленных в ходе проведения мультипараметрической МРТ. Применение данной технологии может увеличить число выявленных случаев рака среднего и высокого рисков (клинически значимого рака), что, в свою очередь, позволить применять более персонализированный подход к лечению этой группы пациентов.

The incidence of prostate cancer with standard biopsy ranges from 31 to 42 %, but the number of false-negative results remains excessively high. Modern urological trends in the diagnosis of prostate cancer are reduced to the identification of the most malignant tumor node (index lesion), which in fact will determine the disease prognosis and treatment tactics of a particular patient. In this paper, the technique of the procedure and the first results of the MRI / US imaging fusion biopsy – technology is described, which allows to perform targeted biopsy of the prostate gland from the nodules, revealed during the multiparameter MRI, are demonstrated. The use of this technology can increase the number of detected cases of middle and high risk cancer (clinically significant cancer), which allows a more personalized approach to the treatment of this group of patients.

рак предстательной железыМРТ/УЗИ fusion-биопсиямультипараметрическая МРТстандартная биопсияклинически значимый ракprostate cancerMRI/ultrasound fusion prostate biopsymultiparametric MRIstandard prostate biopsyclinically significant prostate cancerReferencesScattoni V., Maccagnano C., Capitanio U. et al.Random biopsy: When, how many and where to take the cores? // World J. Urol. 2014. Vol. 32. P. 859–869. doi:10.1007/s00345-014-1335-0Scattoni V., Maccagnano C., Capitanio U. et al.Random biopsy: When, how many and where to take the cores? // World J. Urol. 2014. Vol. 32. P. 859–869. doi:10.1007/s00345-014-1335-0Presti J.C. Prostate biopsy: How many cores are enough? // Urol. Oncol.: Sem. Original Investig. 2003. P. 135–140. doi:10.1016/ S1078-1439(03)00006-1Presti J.C. Prostate biopsy: How many cores are enough? // Urol. Oncol.: Sem. Original Investig. 2003. P. 135–140. doi:10.1016/ S1078-1439(03)00006-1Bjurlin M.A., Wysock J.S., Taneja S.S. Optimization of prostate biopsy: Review of technique and complications // Urol. Clin. North Amer. 2014. Vol. 41. P. 299–313. doi:10.1016/j. ucl.2014.01.011Bjurlin M.A., Wysock J.S., Taneja S.S. Optimization of prostate biopsy: Review of technique and complications // Urol. Clin. North Amer. 2014. Vol. 41. P. 299–313. doi:10.1016/j. ucl.2014.01.011Djavan B., Milani S., Remzi M. Prostate biopsy: who, how and when. An update // Can. J. Urol. 2005. Vol. 12. Suppl 1.Djavan B., Milani S., Remzi M. Prostate biopsy: who, how and when. An update // Can. J. Urol. 2005. Vol. 12. Suppl 1.Rodríguez-Covarrubias F., González-Ramírez A., AguilarDavidov B. et al. Extended sampling at first biopsy improves cancer detection rate: Results of a prospective, randomized trial comparing 12 versus 18-core prostate biopsy // J. Urol. 2011. Vol. 185. P. 2132–2136. doi:10.1016/j.juro.2011.02.010Rodríguez-Covarrubias F., González-Ramírez A., AguilarDavidov B. et al. Extended sampling at first biopsy improves cancer detection rate: Results of a prospective, randomized trial comparing 12 versus 18-core prostate biopsy // J. Urol. 2011. Vol. 185. P. 2132–2136. doi:10.1016/j.juro.2011.02.010Ploussard G., Nicolaiew N., Marchand C. et al. Prospective evaluation of an extended 21-core biopsy scheme as initial prostate cancer diagnostic strategy // Eur. Urol. 2014. Vol. 65. P. 154–161. doi:10.1016/j.eururo.2012.05.049Ploussard G., Nicolaiew N., Marchand C. et al. Prospective evaluation of an extended 21-core biopsy scheme as initial prostate cancer diagnostic strategy // Eur. Urol. 2014. Vol. 65. P. 154–161. doi:10.1016/j.eururo.2012.05.049Weiner A.B., Patel S.G., Etzioni R. et al. National trends in the management of low and intermediate risk prostate cancer in the United States // J. Urol. 2015. Vol. 193. P. 95–102. doi:10.1016/j.juro.2014.07.111Weiner A.B., Patel S.G., Etzioni R. et al. National trends in the management of low and intermediate risk prostate cancer in the United States // J. Urol. 2015. Vol. 193. P. 95–102. doi:10.1016/j.juro.2014.07.111Pokorny M.R., De Rooij M., Duncan E. et al. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies // Eur. Urol. 2014. Vol. 66. P. 22–29. doi:10.1016/j.eururo.2014.03.002Pokorny M.R., De Rooij M., Duncan E. et al. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies // Eur. Urol. 2014. Vol. 66. P. 22–29. doi:10.1016/j.eururo.2014.03.002Sonn G.A., Chang E., Natarajan S. et al. Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen // Eur. Urol. 2014. Vol. 65. P. 809–815. doi:10.1016/j.eururo.2013.03.025Sonn G.A., Chang E., Natarajan S. et al. Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen // Eur. Urol. 2014. Vol. 65. P. 809–815. doi:10.1016/j.eururo.2013.03.025Weinreb J.C., Barentsz J.O., Choyke P.L. et al. PI-RADS Prostate Imaging – Reporting and Data System: 2015, Version 2 // Eur. Urol. 2016. Vol. 69. P. 16–40. doi:10.1016/j.eururo.2015.08.052Weinreb J.C., Barentsz J.O., Choyke P.L. et al. PI-RADS Prostate Imaging – Reporting and Data System: 2015, Version 2 // Eur. Urol. 2016. Vol. 69. P. 16–40. doi:10.1016/j.eururo.2015.08.052Barentsz J.O., Richenberg J., Clements R. et al. ESUR prostate MR guidelines 2012 // Eur. Radiol. 2012. Vol. 22. P. 746–757. doi:10.1007/s00330-011-2377-yBarentsz J.O., Richenberg J., Clements R. et al. ESUR prostate MR guidelines 2012 // Eur. Radiol. 2012. Vol. 22. P. 746–757. doi:10.1007/s00330-011-2377-ySomford D.M., Hamoen E.H., Utterer J.J. et al. The predictive value of endorectal 3 tesla multiparametric magnetic resonance imaging for extraprostatic extension in patients with low, intermediate and high risk prostate cancer // J. Urol. 2013. Vol. 190. P. 1728–1734. doi:10.1016/j.juro.2013.05.021Somford D.M., Hamoen E.H., Utterer J.J. et al. The predictive value of endorectal 3 tesla multiparametric magnetic resonance imaging for extraprostatic extension in patients with low, intermediate and high risk prostate cancer // J. Urol. 2013. Vol. 190. P. 1728–1734. doi:10.1016/j.juro.2013.05.021Delongchamps N.B., Zerbib M. Role of magnetic resonance imaging before initial biopsy: Comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection // Eur. Urol. 2012. Vol. 61. P. 622–623. doi:10.1016/j.eururo.2011.12.038Delongchamps N.B., Zerbib M. Role of magnetic resonance imaging before initial biopsy: Comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection // Eur. Urol. 2012. Vol. 61. P. 622–623. doi:10.1016/j.eururo.2011.12.038Hoeks C.M.A., Schouten M.G., Bomers J.G.R. et al. ThreeTesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: Detection of clinically significant prostate cancers // Eur. Urol. 2012. Vol. 62. P. 902–909. doi:10.1016/j.eururo.2012.01.047Hoeks C.M.A., Schouten M.G., Bomers J.G.R. et al. ThreeTesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: Detection of clinically significant prostate cancers // Eur. Urol. 2012. Vol. 62. P. 902–909. doi:10.1016/j.eururo.2012.01.047Rosenkrantz A.B., Verma S., Choyke P. et al. Prostate magnetic resonance imaging and magnetic resonance imaging targeted biopsy in patients with a prior negative biopsy: a consensus statement by AUA and SAR // J. Urol. 2016. Vol. 196. P. 1613– 1618. doi:10.1016/j.juro.2016.06.079Rosenkrantz A.B., Verma S., Choyke P. et al. Prostate magnetic resonance imaging and magnetic resonance imaging targeted biopsy in patients with a prior negative biopsy: a consensus statement by AUA and SAR // J. Urol. 2016. Vol. 196. P. 1613– 1618. doi:10.1016/j.juro.2016.06.079Cash H., Maxeiner A., Stephan C. et al. The detection of significant prostate cancer is correlated with the Prostate Imaging Reporting and Data System (PI-RADS) in MRI/transrectal ultrasound fusion biopsy // World J. Urol. 2016. Vol. 34. P. 525– 32. doi:10.1007/s00345-015-1671-8Cash H., Maxeiner A., Stephan C. et al. The detection of significant prostate cancer is correlated with the Prostate Imaging Reporting and Data System (PI-RADS) in MRI/transrectal ultrasound fusion biopsy // World J. Urol. 2016. Vol. 34. P. 525– 32. doi:10.1007/s00345-015-1671-8

The authors declare that there are no conflicts of interest present.